Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.
Skip to main content

FULL TITLE

A new treatment for pre-eclampsia. 

OVERVIEW

Proof-of-Concept Trial on Selective Removal of the Antiangiogenic Factor Soluble Fms-like Tyrosine Kinase-1 (sFlt-1) in Pregnant Women with Preeclampsia via Apheresis Utilizing the Flt-1 Adsorption Column.

WHO CAN PARTICIPATE IN THIS STUDY? 

Pregnant women with pre-eclampsia before 32 weeks gestation

ABOUT THE STUDY 

Pre-eclampsia is a potentially serious condition that can put the health and wellbeing of the mother and the baby at risk. There are no effective treatments for pre-eclampsia, except to get the baby out (delivery). However, premature birth can lead to health problems for the baby. Babies born very prematurely may not be able to survive. Now, a clinical trial is being carried out to test whether a new medical device could effectively and safely treat pre-eclampsia.

Abnormally high levels of a protein called sFIt-1 can be found in the blood of pregnant women with pre-eclampsia. This protein is thought to cause many of the problems that occur with pre-eclampsia. The new treatment uses an approach called apheresis to reduce the level of the sFlt-1 protein in the mother’s blood. This is done by circulating the mother’s blood through a machine, using a filter to remove the protein before returning blood to the mother. In some ways, this is similar to the dialysis treatment kidney patients receive.

ETHICAL APPROVAL 

REC reference 16/SC/0200

CONTACT US TO GET INVOLVED 

If you are interested in taking part, you can use our contact form, or  call 01865 572258 or email osprea@wrh.ox.ac.uk